ArticleHaematologica2018
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a
Open access · goldAbstract readClinical Trial, Phase I
In one paragraph
Article in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Integrated Genomic and Tumor Microenvironment Subtyping Improved Risk Stratification in Primary Central Nervous System Lymphoma.American journal of hematology · 2026Article
- Epigenetic mechanisms of drug resistance in acute myeloid leukemia: advances in small-molecule targeted therapy.Frontiers in pharmacology · 2025Review
- Impact of Histone Lysine Methyltransferase SUV4-20H2 on Cancer Onset and Progression with Therapeutic Potential.International journal of molecular sciences · 2024Review
- Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies.Journal of biomedical science · 2020Review
- Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.Chinese medical journal · 2020Review
- Relapsed or primary refractory AML: moving past MEC and FLAG-ida.Current opinion in hematology · 2020Review
- Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia.Cancer gene therapy · 2020Review
- HDAC Inhibitors in Acute Myeloid Leukemia.Cancers · 2019Review
- Epigenetic Modifications in Acute Myeloid Leukemia: Prognosis, Treatment, and Heterogeneity.Frontiers in genetics · 2019Review
- The rocky road to personalized medicine in acute myeloid leukaemia.Journal of cellular and molecular medicine · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 4 institutions in 1 country.
Alice S MimsDivision of Hematology, Department of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH alice.mims@osumc.edu.
Anjali MishraDepartment of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Shelley OrwickDepartment of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
James BlachlyDivision of Hematology, Department of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Rebecca B KlisovicDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA.
Ramiro GarzonDivision of Hematology, Department of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Alison R WalkerDivision of Hematology, Department of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Steven M DevineDivision of Hematology, Department of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Katherine J WalshDivision of Hematology, Department of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Sumithira VasuDivision of Hematology, Department of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Susan WhitmanDepartment of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Guido MarcucciDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.
Daniel JonesDepartment of Pathology, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Nyla A HeeremaDepartment of Pathology, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Gerard LozanskiDepartment of Pathology, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Michael A CaligiuriDepartment of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Clara D BloomfieldDivision of Hematology, Department of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
John C ByrdDivision of Hematology, Department of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
Richard PiekarzInvestigational Drug Branch of CTEP, National Cancer Institute, Bethesda, MD, USA.
Michael R GreverDivision of Hematology, Department of Medicine, The Ohio State University and The Ohio State University Comprehensive Cancer Center, Columbus, OH.
William BlumDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA.
The Ohio State University · USEmory University · USCity Of Hope National Medical Center · USNational Cancer Institute · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MUM1 Supplement for Early Therapeutic Trials with Phase 2 IntentUM1CA186712 · NCI · OHIO STATE UNIVERSITY · PI SUSANNE M ARNOLD, WILLIAM E. CARSON · 2014 to 2026
$19.3MSPORE Leukemia Tissue BankP50CA140158 · NCI · OHIO STATE UNIVERSITY · PI BLOOMFIELD, CLARA D · 2009 to 2013
$11.2MPHASE I TRIALS OF ANTICANCER AGENTSU01CA076576 · NCI · OHIO STATE UNIVERSITY · PI GREVER, MICHAEL R · 1998 to 2013
$9.1MNCI NIH HHS P30 CA016058NCI NIH HHS P50 CA140158NCI NIH HHS U01 CA076576NCI NIH HHS UM1 CA186712
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene DuplicationTandem Repeat SequencesAdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkersDrug ResistanceFemaleHistone-Lysine N-MethyltransferaseHumansLeukemia, Myeloid, AcuteMaleMiddle AgedMyeloid-Lymphoid Leukemia ProteinRecurrenceRetreatmentYoung AdultBiomarkersHistone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.